Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Change in Account Payables: 2021-2024

Historic Change in Account Payables for NewAmsterdam Pharma Co N.V (NAMS) over the last 4 years, with Dec 2024 value amounting to -$12.9 million.

  • NewAmsterdam Pharma Co N.V's Change in Account Payables fell 219.11% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.6 million, marking a year-over-year decrease of 214.73%. This contributed to the annual value of -$12.9 million for FY2024, which is 355.38% down from last year.
  • NewAmsterdam Pharma Co N.V's Change in Account Payables amounted to -$12.9 million in FY2024, which was down 355.38% from $5.1 million recorded in FY2023.
  • NewAmsterdam Pharma Co N.V's 5-year Change in Account Payables high stood at $6.6 million for FY2021, and its period low was -$12.9 million during FY2024.
  • In the last 3 years, NewAmsterdam Pharma Co N.V's Change in Account Payables had a median value of $4.8 million in 2022 and averaged -$1.0 million.
  • In the last 5 years, NewAmsterdam Pharma Co N.V's Change in Account Payables increased by 5.43% in 2023 and then plummeted by 355.38% in 2024.
  • Yearly analysis of 4 years shows NewAmsterdam Pharma Co N.V's Change in Account Payables stood at $6.6 million in 2021, then fell by 26.67% to $4.8 million in 2022, then grew by 5.43% to $5.1 million in 2023, then slumped by 355.38% to -$12.9 million in 2024.